Radiochemistry for positron emission tomography

J Rong, A Haider, TE Jeppesen, L Josephson… - Nature …, 2023 - nature.com
Positron emission tomography (PET) constitutes a functional imaging technique that is
harnessed to probe biological processes in vivo. PET imaging has been used to diagnose …

Updates in diagnosis, management, and treatment of neuroblastoma

CC Swift, MJ Eklund, JM Kraveka, AL Alazraki - Radiographics, 2018 - pubs.rsna.org
Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. It is the
most common extracranial solid tumor of childhood and accounts for up to 15% of all …

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

JJ Zaknun, L Bodei, J Mueller-Brand, ME Pavel… - European journal of …, 2013 - Springer
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

MF Bozkurt, I Virgolini, S Balogova, M Beheshti… - European journal of …, 2017 - Springer
Abstract Purpose & Methods Neuroendocrine neoplasms are a heterogenous group of
tumours, for which nuclear medicine plays an important role in the diagnostic work-up as …

Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation

MS Hofman, WFE Lau, RJ Hicks - Radiographics, 2015 - pubs.rsna.org
Gallium 68 (68Ga) 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)–
octreotate (DOTATATE, GaTate) positron emission tomography (PET)/computed tomography …

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and …

SM Sadowski, V Neychev, C Millo, J Shih… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) are increasing in
incidence, and accurate staging is important for selecting the appropriate treatment. 68Ga …

ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy

G Sgouros, WE Bolch, A Chiti… - Journal of the …, 2021 - journals.sagepub.com
The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

Prospective of 68Ga-radiopharmaceutical development

I Velikyan - Theranostics, 2013 - pmc.ncbi.nlm.nih.gov
Positron Emission Tomography (PET) experienced accelerated development and has
become an established method for medical research and clinical routine diagnostics on …

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

L Bodei, M Cremonesi, CM Grana, N Fazio… - European journal of …, 2011 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2
somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II …

Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT

Y Sanli, I Garg, A Kandathil, T Kendi… - American Journal of …, 2018 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to provide a review of the use of 68Ga
tetraazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a …